Point Biopharma Global

POINT Biopharma Global, Inc. is a precision oncology company, which engages in the development and commercialization of radiopharmaceuticals for the treatment of cancer. It offers CanSEEK, a technology which aims to minimize radiopharmaceutical toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety. The company was founded by Joe McCann and Neil E. Fleshner on April 15, 2020 and is headquartered in Indianapolis, IN.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

POINT Biopharma Global, Inc. is a radiopharmaceutical company. It engages in the business of building a platform for the clinical development and commercialization of radioligands that fight cancer. The company was founded by Joe McCann and Neil E. Fleshner on April 15, 2020 and is headquartered in Indianapolis, IN.

PNT2004 program's phase 1 FRONTIER trial design to be presented Abstract to be released today at 5:00 PM ET, May 25 th Poster to be available starting at 9:00 AM ET, June 3 rd INDIANAPOLIS, May 25, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced an upcoming poster presentation for the Company's ongoing phase 1, pan-cancer, fibroblast activation protein-α (FAP-α)-targeted trial, FRONTIER (NCT05432193), at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago, IL. The Trial-in-Progress poster will include trial background information, study design considerations, and a cohort enrollment status update.

POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO

The company's innovative product pipeline and exclusive CanSEEK technology offer groundbreaking cancer treatments that address unmet clinical needs, positioning POINT for leadership in the biopharma industry. POINT Biopharma recently received FDA Fast Track designation for their advanced 177Lu-PNT2002 therapy, which aims to treat metastatic castration-resistant prostate cancer and fill an unmet medical need.

POINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong Financials

Point Biopharma Global released first-quarter earnings. The company said that its lead therapy had received fast-track designation from the FDA.

Why Shares of Point Biopharma Global Rose Monday

POINT further strengthens supply chain with $10 million investment in Ionetix Alpha Corp. POINT further strengthens supply chain with $10 million investment in Ionetix Alpha Corp.

POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer

U.S. FDA granted Fast Track designation for 177 Lu-PNT2002 for the treatment of mCRPC in April 2023

POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

OmniAb Inc

Verrica Pharmaceuticals Inc

Adicet Bio, Inc.

AC Immune

Altimmune

CorMedix

Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can't just introduce health-related products directly to the market.

7 Biotech Stocks With Huge Return Potential for Long-Term Investors

BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, and POINT Biopharma Global, Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer (mCRPC). Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address unmet medical needs. PNT2002 is an innovative PSMA-targeted 177Lu-based radiopharmaceutical therapy that combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope no-carrier-added 177Lu.

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

AbCellera Biologics

Chimerix

Kiniksa Pharmaceuticals Ltd

Ocuphire Pharma

Vaccitech

Vir Biotechnology

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates

POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

INDIANAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinical trial for the PSMA-targeted PNT2002 program is not experiencing any manufacturing or drug supply issues or delays.

POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

POINT Biopharma Global Inc. has a set of radioligand therapies in various stages. It has a major deal with Lantheus.

Point Biopharma: Interesting, Novel Radiotherapy Developer

INDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced management will participate in the following upcoming investor conferences:

POINT Biopharma to Participate in Upcoming Investor Conferences

Enrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidance Enrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidance

POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial

INDIANAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced that the closing conditions, including Hart-Scott-Rodino antitrust clearance, have been met for the previously announced agreements with Lantheus Holdings Inc. (NASDAQ: LNTH).

POINT Biopharma Announces Closing of Agreements with Lantheus Holdings

Combining 177 Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model

POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy

INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the third quarter ended September 30, 2022, and provided an update on business highlights, including the announcement of a strategic collaboration and exclusive license agreements with Lantheus Holdings Inc. (NASDAQ: LNTH) for the commercialization of PNT2002 & PNT2003.

POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings

Collaboration pairs POINT's expertise in next generation radioligand development and manufacturing with Lantheus' commercial leadership in PSMA PET and radiopharmaceuticals

Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

The average of price targets set by Wall Street analysts indicates a potential upside of 212.4% in POINT Biopharma Global Inc. (PNT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in POINT Biopharma Global Inc. (PNT)? Wall Street Analysts Think 212%

POINT Biopharma (PNT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for POINT Biopharma (PNT)

The consensus price target hints at a 235.3% upside potential for POINT Biopharma Global Inc. (PNT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think POINT Biopharma Global Inc. (PNT) Could Surge 235%: Read This Before Placing a Bet

PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225

POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM's Annual Congress

INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the closing of its previously announced underwritten public offering of 13,900,000 shares of Common Stock at a public offering price of $9.00 per share. The gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $125 million.

POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock

The market didn't react well to news of the biotech's latest financing effort.

Why Point Biopharma Global Stock Got Crushed Today

INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the pricing of its public offering of 13,900,000 shares of Common Stock at a public offering price of $9.00 per share. The gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $125 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 2,085,000 shares of its Common Stock. All of the shares to be sold in the offering are to be sold by POINT. The offering is expected to close on or about September 16, 2022, subject to customary closing conditions.

POINT Biopharma Prices Public Offering of Common Stock

INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced that it has commenced an underwritten public offering of its common stock. In addition, POINT expects to grant the underwriters a 30-day option to purchase up to an additional 15% of its common stock being sold in the offering at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in this offering will be sold by POINT. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or the actual size or terms of the proposed offering.

News for Point Biopharma Global Stock (PNT)